Loading...
ROCO
4117
Market cap20mUSD
Oct 08, Last price  
9.39TWD
1D
9.19%
1Q
-10.57%
Jan 2017
-53.86%
IPO
27.93%
Name

General Biologicals Corp

Chart & performance

D1W1MN
ROCO:4117 chart
P/E
1.42
P/S
3.06
EPS
6.62
Div yield, %
—
Shrs. gr., 5y
2.53%
Rev. gr., 5y
-14.63%
Revenues
216m
-14.36%
239,651,000475,867,000551,658,000370,459,000264,825,000251,926,000215,739,000
Net income
466m
P
-39,046,00062,150,00044,142,000-53,192,000-198,834,000-220,823,000465,840,000
CFO
-127m
L+9.61%
-1,752,00046,741,00038,973,000225,006,000225,684,000-116,110,000-127,263,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally, GBC provides essential blood screening services for detecting hepatitis and HIV, alongside crucial biomaterials such as antibody preparations and human plasma. Venturing beyond diagnostics, the company also markets a line of oral care products under its proprietary 'oh care' brand. These diagnostic systems are primarily utilized by clinics and laboratories. Founded in 1973, General Biologicals Corporation is headquartered in Hsinchu City, Taiwan.

Key people

Tsong Chin Lin
Chairman of the Board · since 2018
Frank Lin
General Manager, Director · since 2018
Deputy General Manager · since 2013
Jinmei Shi
Head of Finance & Accounting · since 2024
Director · since 2020
Director · since 2025
Ruixun Chen
Independent Director · since 2025
Chenghua Li
Independent Director · since 2025
Cheryl Lin
Independent Director · since 2018
Jen-Leih Wu
Independent Director · since 2018
IPO date
Jul 04, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT